Despite this, the sub-analysis indicates that patients with NVAF and diabetes, compared to patients with NVAF without diabetes, derive similar relative outcomes from PRADAXA 150mg or dabigatran 110mg compared to warfarin.???It is common for patients with atrial fibrillation to have co-morbidities, such as diabetes,??? said Harald Darius, MD, PhD, Vivantes Berlin-Neuk??lln Medical Center, Germany.